Last reviewed · How we verify
Tagamet (CIMETIDINE)
Tagamet (Cimetidine) is a small molecule Histamine-2 Receptor Antagonist developed by Smith, Kline & French, currently owned by Glaxosmithkline. It targets the histamine H2 receptor to reduce stomach acid production, treating conditions such as duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease. Tagamet was FDA approved in 1977 and is now off-patent with 19 generic manufacturers. Key safety considerations include potential interactions with other medications and effects on the liver. It has a half-life of 2.2 hours and 60% bioavailability.
At a glance
| Generic name | CIMETIDINE |
|---|---|
| Sponsor | Glaxosmithkline |
| Drug class | Histamine-2 Receptor Antagonist [EPC] |
| Target | Histamine H2 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1977 |
Approved indications
- Duodenal ulcer disease
- Gastric ulcer
- Gastroesophageal reflux disease
- Heartburn
- Indigestion
- Maintenance of Healing Duodenal Ulcer
- Multiple endocrine adenomas
- Systemic mast cell disease
- Upper GI Bleed Prevention
- Upper gastrointestinal hemorrhage
- Zollinger-Ellison syndrome
Common side effects
- Headaches
- Dizziness
- Somnolence
- Gynecomastia
- Reversible impotence
- Decreased white blood cell counts
- Agranulocytosis
- Thrombocytopenia
- Pancytopenia or aplastic anemia
- Immune hemolytic anemia
- Dose-related increases in serum transaminase
- Cholestatic or mixed cholestatic-hepatocellular effects
Drug interactions
- choline theophyllinate
- cisapride
- clomipramine
- clopidogrel
- clozapine
- dasatinib
- dicoumarol
- dofetilide
- doxepin
- enoxacin
- erlotinib
- estazolam
Key clinical trials
- Zimmer Biomet-RibFix Titan
- Dual vs. Single-Antibiotic Impregnated Cement in Hemiarthroplasty for Femoral Neck Fracture (PHASE3)
- ROSA® Knee System V1.5 Pilot Study (NA)
- An MRI Investigation of Soft Tissues in Total Hip Arthroplasty
- Comparison of Artificial Disc Implants in Cervical Disc Arthroplasty
- Effect of Oral Cimetidine in the Protoporphyrias (PHASE2)
- Study of Zimmer Biomet Mymobility Application on Reverse Total Shoulder Arthroplasty (RTSA) Outcomes (NA)
- Persona Cohort Nordic Multicenter Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |